Google
CERT Stock Analysis — CERTARA INC (Healthcare >> Health Information Services)
CERT FAQ
What is CERT's P/E ratio?
CERTARA INC (CERT) currently trades at a P/E ratio of -2,732.04.
What is CERT's ROE?
CERTARA INC reports a Return on Equity (ROE) of -1.48%.
What is CERT's dividend yield?
CERTARA INC offers a dividend yield of 0.00%.
What is CERT's Quality Score?
Our AI rates CERT's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CERT?
Our AI Timing Score for CERT is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CERT belong to?
CERTARA INC is classified under the Healthcare >> Health Information Services sector on the NASDAQ exchange
CERT AI Analysis Summary
Our AI summary for CERT: CERTARA INC (NASDAQ), Healthcare >> Health Information Services sector. The stock currently trades at a P/E of -2,732.04, ROE of -1.48%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 8.10
Price
0.32
(4.11%)
Day Change
|
|
|---|
CERT, the overall quality is not quite good ( Quality = 54) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 8.10 |
| PBV / Sector |
1.19 / 6.33
GREAT
|
| Earning Per Share | -0.10 |
| PE / Sector |
N/A / 46.50
|
| PEG or PE/Growth / Sector |
12.77 / -0.41
|
| Average 1M Daily Value |
26.66 M
GREAT
|
| Average 1W Daily Value |
35.95 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 07:59:37 |
| Symbol | CERT |
| Name | CERTARA INC |
| Sector | Healthcare >> Health Information Services |
| Market | NASDAQ |
| Listed Shares | 155.56 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,210.29 / 4,079.00 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 4 Radnor Corporate Center, Radnor, PA, United States, 19087
Phone: 415 237 8272
Website: https://www.certara.com
Employees: 1,515
Description: Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Health Information Services
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › Health Information ServicesAnalysed on the same criteria, ordered by market cap